Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the… Read More »Stocks to Watch: Lexaria Bioscience (LEXX.Q) sees gains
Today, Kieran Robertson breaks down what he thinks about Lexaria Bioscience (LEXX.Q), a biotech that has developed a patented drug delivery technology, DehydraTECH, to improve… Read More »Lexaria Bioscience (LEXX.Q) – Three Minute Hits Video
Eye Don’t Believe It Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be… Read More »Don’t sit so close to the TV! (Sector Roundup: Week 11)
Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so… Read More »The Millennial sweet tooth (Sector Roundup: Week 10)
Smart Watch, Healthy Heart There was an opportunity for a pun in the headline and I took it. In this week’s sector roundup, we… Read More »Apple & Google are “watching” your heart, literally (Sector Roundup: Week 7)
Digital Medicine Society The world is on fire, inflation is through the roof, and there is a literal war occurring in Ukraine. While I… Read More »Drugmakers Assemble! (Sector Roundup: Week 5)
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering… Read More »A Trip Down Memory Lane (Sector Roundup: Week 2)
Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores… Read More »Lexaria Bioscience’s (LEXX.Q) DehydraTECH™ Enabled Consumer Products Now Available in Over 7,000 Stores
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also… Read More »Lexaria Bioscience (LEXX.Q) Completes Dosing in Human Clinical Study HYPER-H21-2
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. Read full article here: https://equity.guru/2021/07/lexaria-bioscience-lexx-q-announces-positive-results-for-viral-a20-3-study-shares-climb-66/
